Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study.
Nathaniel Aviv CohenNikolas PlevrisUri KopylovAnna GrinmanBella UngarHenit YanaiHaim LeibovitzhNaomi Fliss IsakovAyal HirschEinat RitterYulia RonAriella Bar-Gil ShitritEran GoldinIris DotanShomron Ben HorinCharlie W LeesNitsan MaharshakPublished in: United European gastroenterology journal (2020)
Vedolizumab is equally effective in elderly and young inflammatory bowel disease patients. The findings of this study demonstrate an increased risk of infections among the elderly treated with vedolizumab, which may be related to their age and underlying diseases.